ライフサイエンスコーパス: herpes zoster

1 s for the treatment of VZV infections (i.e., herpes zoster).

2 s a highly contagious agent of varicella and herpes zoster.

3 VZV) is the causative agent of varicella and herpes zoster.

4 ia and can reactivate later in life to cause herpes zoster.

5 are transiently increased after exposure to herpes zoster.

6 isk of acute cardiovascular events following herpes zoster.

7 duals in comparison with patients with acute herpes zoster.

8 en chronic obstructive pulmonary disease and herpes zoster.

9 a small but significantly increased risk of herpes zoster.

10 geminal ganglion, in the absence of clinical herpes zoster.

11 ociation between statin use and incidence of herpes zoster.

12 n postvaccination GMT and risk of subsequent herpes zoster.

13 ntion of VZV reactivation and development of herpes zoster.

14 ls >/= 60 years old with a recent episode of herpes zoster.

15 ith a recent episode of clinically diagnosed herpes zoster.

16 n sensory neurons from reactivating to cause herpes zoster.

17 ine was associated with a lower incidence of herpes zoster.

18 ccination remained highly protective against herpes zoster.

19 as 100% (95% CI, 67%-100%; P < .001) against herpes zoster.

20 t to valacyclovir for the treatment of acute herpes zoster.

21 e its clinical efficacy for the treatment of herpes zoster.

22 al copies correlated with the progression of herpes zoster.

23 ts that viremia is a common manifestation of herpes zoster.

24 at >1 variant strain may reactivate to cause herpes zoster.

25 luded meningitis in patients with concurrent herpes zoster.

26 in a long-term-care facility after a case of herpes zoster.

27 fer to skin in the affected dermatome during herpes zoster.

28 the often severe neurologic consequences of herpes zoster.

29 anglia and reactivates from latency to cause herpes zoster.

30 development of novel treatments for painful herpes zoster.

31 tency in sensory ganglia, and reactivates as herpes zoster.

32 at patients with RA are at increased risk of herpes zoster.

33 matological malignancies is at high risk for herpes zoster.

34 on for development of treatments for painful herpes zoster.

35 ced transient local skin reactions: 1 (4.8%) herpes zoster, 3 (14.3%) transaminase elevation, and 1 (

36 nd 31.5% in the 5.25-mg group, vs. 1.8%) and herpes zoster (8 patients and 12 patients, respectively,

37 PORTANCE Varicella-zoster virus (VZV) causes herpes zoster, a major health issue in the aging and imm

38 relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined

39 1.04; 95% confidence interval 1.00-1.08) or herpes zoster (adjusted HR 1.03; 95% confidence interval

40 d indirect influences on the epidemiology of herpes zoster among children.

41 confirmed cases, the incidence of recurrent herpes zoster among persons aged <70 years was 0.99 (95%

42 ecified analysis, we found a similar risk of herpes zoster among statin users in the subgroup of pati

43 e subjects, 1 DZB(-)MMF(-) subject developed herpes zoster and 1 DZB(-)MMF(+) subject had Bell's pals

44 equivalent to about 17 000 fewer episodes of herpes zoster and 3300 fewer episodes of postherpetic ne

45 a vaccine effectiveness of about 62% against herpes zoster and 70-88% against postherpetic neuralgia.

46 ause of malignancy have an increased risk of herpes zoster and herpes zoster-related complications.

47 ine is being developed for the prevention of herpes zoster and its complications.

48 rld-wide, reactivating in one-third to cause herpes zoster and occasionally chronic pain.

49 o estimate vaccine coverage and incidence of herpes zoster and postherpetic neuralgia consultations.

50 es zoster vaccine is effective in preventing herpes zoster and postherpetic neuralgia in immunocompet

51 diagnosis, natural history, and treatment of herpes zoster and postherpetic neuralgia in immunocompet

52 of the vaccination programme on incidence of herpes zoster and postherpetic neuralgia in this populat

53 ultations with patients aged 60-89 years for herpes zoster and postherpetic neuralgia occurring betwe

54 cinations administered and consultations for herpes zoster and postherpetic neuralgia, and aggregated

55 osting VZV-CMI protects older adults against herpes zoster and postherpetic neuralgia.

56 ce-attenuated vaccine against chickenpox and herpes zoster and providing a new target for interventio

57 st (>5%) for oral candidiasis, tuberculosis, herpes zoster, and bacterial pneumonia.

58 neumonia, hepatitis, meningitis, septicemia, herpes zoster, and poliomyelitis), and inflammatory (glo

59 To examine whether herpes zoster antigen (also called varicella-zoster viru

60 Herpes zoster antigen was detected in 3 of 25 temporal a

61 ups of patients, false-positive staining for herpes zoster antigen was detected in the presence of ca

62 False-positive staining for herpes zoster antigen was detected on several temporal a

63 Among the GCA-negative group, herpes zoster antigen was not detected in any biopsy.

64 group, 3 patients had positive staining for herpes zoster antigen.

65 ential approaches to improving prevention of herpes zoster are discussed.

66 he motivating study above, the odds ratio of herpes zoster associated with chronic obstructive pulmon

67 r ITS reporting incidences of chickenpox and herpes zoster before and after implementation of chicken

68 r virus is an important human pathogen, with herpes zoster being a major health issue in the aging an

69 eased incidences of cytomegalovirus disease, herpes zoster, BK virus, and nephropathy, which led to t

70 category, and the annual rates of change in herpes zoster by age category, in an interrupted time se

71 is commonly thought to increase the risk of herpes zoster by causing immunosuppression.

72 n environmental samples from the room of the herpes zoster case patient.

73 The number of herpes zoster cases among vaccinated individuals was 828

74 oups revealed a net increase of hospitalized herpes zoster cases in individuals aged 10-49 years afte

75 No herpes zoster cases or major adverse cardiac events incl

76 users of anti-TNF therapy, we identified 310 herpes zoster cases.

77 PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella

78 port the first laboratory-documented case of herpes zoster caused by the attenuated varicella zoster

79 reased rate of Coccidioides, Salmonella, and herpes zoster compared to children with ADHD.

80 stroke and acute MI in defined periods after herpes zoster compared to other time periods, within ind

81 ted with a significantly higher incidence of herpes zoster compared with dexamethasone treatment (13%

82 nti-TNF therapies were not at higher risk of herpes zoster compared with patients who initiated nonbi

83 from the most commonly used method to obtain herpes zoster data (rates obtained from administrative d

84 Medicare beneficiaries aged >/= 65 y with a herpes zoster diagnosis and either an ischemic stroke (n

85 Risk of herpes zoster differed by vaccination status to a greate

86 c neuralgia is the most important symptom of herpes zoster disease and it is very difficult to treat.

87 c neuralgia is the most important symptom of herpes zoster disease, which is caused by Varicella zost

88 of 17 VZV-seropositive patients experienced herpes zoster during the posttransplant period.

89 ng immunocompetent patients who had a recent herpes zoster episode.

90 human alphaherpesvirus causing varicella and herpes zoster, expresses 24 virally encoded sncRNA (VZVs

91 for the three routine cohorts, incidence of herpes zoster fell by 35% (incidence rate ratio 0.65 [95

92 The adjusted hazard ratios of herpes zoster for patients with RA compared with non-RA

93 activation in the peripheral nervous system (herpes zoster) have been published, while exceedingly fe

94 nation was associated with a reduced risk of herpes zoster (hazard ratio [HR], 0.45; 95% CI, 0.42-0.4

95 CI, 0.23-0.61) and hospitalizations coded as herpes zoster (HR, 0.35; 95% CI, 0.24-0.51) were less li

96 Ophthalmic herpes zoster (HR, 0.37; 95% CI, 0.23-0.61) and hospital

97 ological agent of varicella (chickenpox) and herpes zoster (HZ [shingles]).

98 ive agent of both varicella (chickenpox) and herpes zoster (HZ) (shingles).

99 Herpes zoster (HZ) adversely affects individuals aged 50

100 Each year, herpes zoster (HZ) affects 1 million U.S. adults, many o

101 Worldwide, herpes zoster (HZ) affects millions of patients (particu

102 es have shown a decrease in the incidence of herpes zoster (HZ) among human immunodeficiency virus (H

103 Tens of millions of seniors are at risk of herpes zoster (HZ) and its complications.

104 Herpes zoster (HZ) and postherpetic neuralgia (PHN) caus

105 icians' perception of burden associated with herpes zoster (HZ) and postherpetic neuralgia (PHN), int

106 humoral and cell-mediated immunity (CMI) to herpes zoster (HZ) and protection against HZ morbidity a

107 The primary reported risk factors for herpes zoster (HZ) are increasing age and immunodeficien

108 Risk factors for herpes zoster (HZ) are poorly defined.

109 n LTPS decreased from 61.1% to 37.3% for the herpes zoster (HZ) burden of illness (BOI), from 66.5% t

110 Vaccine efficacy for herpes zoster (HZ) burden of illness, incidence of posth

111 Vaccine-strain herpes zoster (HZ) can occur after varicella vaccination

112 lined following varicella vaccine licensure, herpes zoster (HZ) cases may play a larger role in varic

113 varicella vaccination on the epidemiology of herpes zoster (HZ) critically depends on the mechanism o

114 The incidence of herpes zoster (HZ) has been increasing in recent decades

115 on emergency department (ED) utilization for herpes zoster (HZ) has not been examined to date.

116 Temporal increases in the incidence of herpes zoster (HZ) have been reported but studies have e

117 A vaccine to prevent herpes zoster (HZ) in adults > or =60 years of age with

118 troviral therapy (HAART) on the incidence of herpes zoster (HZ) in human immunodeficiency virus (HIV)

119 The risk for herpes zoster (HZ) in patients with psoriasis treated wi

120 ination program might lead to an increase in herpes zoster (HZ) incidence has been supported by model

121 dom (UK) due to concerns this could increase herpes zoster (HZ) incidence.

122 The primary reported risk factors for herpes zoster (HZ) include increasing age and immunodefi

123 The incidence and severity of herpes zoster (HZ) increases with age.

124 Protection against herpes zoster (HZ) induced by the live attenuated zoster

125 compromised adults are at .increased risk of herpes zoster (HZ) infection and related complications.

126 ocompromised adults are at increased risk of herpes zoster (HZ) infection and related complications.

127 Herpes zoster (HZ) is common and often severe in patient

128 ostherpetic neuralgia (PHN) risk by reducing herpes zoster (HZ) occurrence, it is less clear whether

129 Efficacy of the live-attenuated herpes zoster (HZ) vaccine (ZVL) wanes substantially ove

130 e in a healthy population, the protection of herpes zoster (HZ) vaccine in end-stage renal disease (E

131 Based on limited data, the live attenuated herpes zoster (HZ) vaccine is contraindicated in patient

132 Understanding long-term effectiveness of herpes zoster (HZ) vaccine is critical for determining v

133 The adjuvanted recombinant glycoprotein E herpes zoster (HZ) vaccine is superior to the live atten

134 Herpes zoster (HZ) vaccine was recommended in the United

135 Recombinant herpes zoster (HZ) vaccines may be an alternative to the

136 nfected individuals are at increased risk of herpes zoster (HZ), even in the antiretroviral therapy (

137 cine recipients with postvaccination rash or herpes zoster (HZ), focusing on polymorphisms between li

138 Data on the epidemiology of herpes zoster (HZ), particularly in the unvaccinated imm

139 Data on the epidemiology of herpes zoster (HZ), particularly in the unvaccinated, im

140 mmunologic factors that modulate the risk of herpes zoster (HZ), we compared varicella-zoster virus (

141 kenpox and reactivation of latent VZV causes herpes zoster (HZ).

142 ency, and in rare cases, reactivate to cause herpes zoster (HZ).

143 ine efficacy (VE) to reduce the incidence of herpes zoster (HZ).

144 ster virus and thereby increase incidence of herpes zoster (HZ).

145 and it can reactivate later in life, causing herpes zoster (HZ).

146 and decreases the incidence and severity of herpes zoster (HZ).

147 vaccine in older adults following documented herpes zoster (HZ).

148 ection, as well as reactivation resulting in herpes zoster (HZ).

149 , establish latency, and reactivate to cause herpes zoster (HZ).

150 from which it can later reactivate to cause herpes zoster (HZ).

151 healthy individuals >60 years of age against herpes zoster (HZ).

152 pain, which later was clinically found to be herpes zoster (HZ).

153 ological agent of varicella (chickenpox) and herpes zoster (HZ, shingles).

154 g of oral acyclovir reduces the incidence of herpes zoster in a randomized, double-blind, placebo-con

155 Although the annual incidence of herpes zoster in adults has continued to increase, the r

156 ated varicella-zoster virus vaccine prevents herpes zoster in adults older than 50 years.

157 su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or olde

158 1 g TID versus 2 g TID, for the treatment of herpes zoster in immunocompromised patients > or =18 yea

159 has a substantial population-level impact on herpes zoster in nonvaccinated age groups.

160 binant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoieti

161 mpared with placebo, in reducing the risk of herpes zoster in older adults.

162 billing code data identified 1,959 cases of herpes zoster in Olmsted County, Minnesota, adults betwe

163 , educate, and prescribe the vaccine against herpes zoster in order to increase utilization of this v

164 three serious infections, and four cases of herpes zoster in patients who received tofacitinib durin

165 Estimated vaccine efficacy against herpes zoster in patients with solid tumour malignancies

166 tios for the incidence rates of varicella or herpes zoster in vaccinated versus unvaccinated children

167 acyclovir prophylaxis significantly reduced herpes zoster incidence among HIV-infected persons.

168 Accurate rates of herpes zoster incidence and complication have become of

169 lysis on impact of chickenpox vaccination on herpes zoster incidence and time trend, focusing on popu

170 The increase in age-adjusted herpes zoster incidence before implementation of chicken

171 models to compare propensity score-adjusted herpes zoster incidence between new anti-TNF and nonbiol

172 We compared herpes zoster incidence between new anti-TNF users (n=33

173 In the antiretroviral therapy era, herpes zoster incidence continued to decline in people l

174 The primary efficacy endpoint was herpes zoster incidence in patients with solid tumour ma

175 Herpes zoster incidence increases with bortezomib.

176 MAIN OUTCOME MEASURES: Herpes zoster incidence rate within 42 days after vaccin

177 Herpes zoster incidence rates have continued to increase

178 Historic herpes zoster incidence trends in US adults have been ha

179 ccine effectiveness, duration of protection, herpes zoster incidence, and probability of postherpetic

180 ; IRR 3.8 [95% CI 1.2-9.5]), and 32 cases of herpes zoster (incidence rate 225 per 100,000 person-yea

181 on for the four catch-up cohorts was 33% for herpes zoster (incidence rate ratio 0.67 [0.61-0.74]) an

182 tegories during 1996-2006 and 2007-2016, the herpes zoster incidences increased at annual rates of 1-

183 In 1991-1995, the herpes zoster incidences increased at annual rates of 4-

184 The annual incidences of herpes zoster increased throughout the period of 1991-20

185 that is the causative agent of varicella and herpes zoster, induces formation of the NLRP3 inflammaso

186 nine aminotransferase (29 [8%] vs six [2%]), herpes zoster infection (nine [3%] vs three [1%]), hyper

187 sis showed a significant increase in risk of herpes zoster infection among patients who received JAK

188 meta-analysis, we found an increased risk of herpes zoster infection among patients with immune-media

189 Disproportionality in reporting herpes zoster infection was higher for patients receivin

190 Herpes zoster infection was reported in 6% of patients i

191 oups, and the rates of overall infection and herpes zoster infection were higher with tofacitinib tha

192 Incidence rates of serious infections, herpes zoster infection, malignancy, and major cardiovas

193 mated incidence rates of serious infections, herpes zoster infection, non-melanoma skin cancer, other

194 ve fibre density, comparable to that seen in herpes zoster infection.

195 % CI, 2.26-2.91]); the proportion of serious herpes zoster infections was not higher than the proport

196 Most herpes zoster infections were grade 1/2; incidences of g

197 s, there were four serious infections, three herpes zoster infections, one myocardial infarction, and

198 a; recurrent, severe herpes simplex virus or herpes zoster infections; extensive and persistent infec

199 Herpes zoster is a common late complication of varicella

200 s with rheumatoid arthritis (RA) and whether herpes zoster is associated with use of disease-modifyin

201 Herpes zoster is common and can have serious consequence

202 Herpes zoster is common and has serious consequences, no

203 Herpes zoster is common and vaccine preventable.

204 To determine whether the incidence of herpes zoster is elevated in patients with rheumatoid ar

205 protein E (gE) subunit vaccine candidate for herpes zoster is in development.

206 Herpes zoster is linked to amyloid-associated diseases,

207 owever, whether statins increase the risk of herpes zoster is unknown.

208 s vaccine in preventing varicella-zoster and herpes zoster is well documented, as are many of the mut

209 petic eye disease (due to herpes simplex and herpes zoster) is a significant cause of visual impairme

210 ren and young adults, potentially leading to herpes zoster later in life on reactivation from latency

211 No serious infections, herpes zoster, malignancy, venous thromboembolic events,

212 ion of chickenpox vaccination, incidences of herpes zoster may rise.

213 Serious adverse events included herpes zoster (n = 2), influenza, and pneumonia.

214 Approximately 1 million episodes of herpes zoster occur annually in the United States.

215 5175 person-years of follow-up, 26 cases of herpes zoster occurred among those assigned acyclovir, c

216 ied intention-to-treat population, confirmed herpes zoster occurred in 22 of 1328 (6.7 per 1000 perso

217 After inoculation, herpes zoster occurred in 7 vaccine recipients versus 24

218 of biologic DMARDs alone was associated with herpes zoster (odds ratio [OR] 1.54, 95% CI 1.04-2.29),

219 ulopathy (2.3%), cranial nerve palsies (2%), herpes zoster ophthalmicus (HZO) (1.2%), and HIV retinop

220 eatment of ophthalmoplegia in the setting of herpes zoster ophthalmicus (HZO) is controversial.

221 ospital-based epidemiology study to describe herpes zoster ophthalmicus (HZO) prevalence and risk fac

222 Herpes zoster ophthalmicus (HZO), thought to be a unilat

223 Herpes zoster ophthalmicus and scleritis/episcleritis IC

224 ical record can reliably be used to identify herpes zoster ophthalmicus cases.

225 s was noteworthy because the patient had had herpes zoster ophthalmicus diagnosed 3 weeks before the

226 Eyes with herpes zoster ophthalmicus had a significant (P<0.001) d

227 Herpes zoster ophthalmicus occurs primarily in elderly o

228 We report a case of herpes zoster ophthalmicus-related ophthalmoplegia (HZOR

229 se of traditional DMARDs was associated with herpes zoster (OR 1.27, 95% CI 1.10-1.48).

230 cts a transient increase in the incidence of herpes zoster, peaking in adults 15-35 years after the s

231 Outcome measures were the incidences of herpes zoster per 100 000 person-years, by calendar year

232 The hypothesized increase in herpes zoster predicted from modelling of the exogenous

233 ting wild-type varicella delays the onset of herpes zoster, predicts a transient increase in the inci

234 ng chemotherapy, but was not efficacious for herpes zoster prevention in patients with haematological

235 ccine was well tolerated and efficacious for herpes zoster prevention in patients with solid tumour m

236 ted varicella zoster virus (VZV) vaccine for herpes zoster prevention in patients with solid tumour o

237 Herpes zoster prophylaxis is necessary with BDR, and rev

238 Only 11 patients (42%) had a concomitant herpes zoster rash.

239 = 1 for each) were grade 3 hyponatremia and herpes zoster reactivation and grade 4 neutropenia.

240 Herpes zoster reactivation disproportionately affects pa

241 No additional risk factors for herpes zoster reactivation were identified.

242 ion between vaccination and the incidence of herpes zoster recurrence among persons with a recent epi

243 The risk of herpes zoster recurrence following a recent initial epis

244 of oral corticosteroids was associated with herpes zoster regardless of concomitant therapies.

245 have an increased risk of herpes zoster and herpes zoster-related complications.

246 were similar between treatment arms, and no herpes zoster-related deaths occurred.

247 Among 697 herpes zoster reports, PCR analysis identified Oka VZV i

248 f the first seven treated patients developed herpes zoster, resulting in the institution of prophylac

249 necrosis factor (anti-TNF) therapy elevates herpes zoster risk.

250 o examine the effect of current treatment on herpes zoster risk.

251 Herpes zoster (shingles) causes significant morbidity in

252 he agent causing varicella (chicken pox) and herpes zoster (shingles), we generated a full-length inf

253 VZV causes varicella (chicken pox) and herpes zoster (shingles), while HCMV causes serious dise

254 ological agent of varicella (chickenpox) and herpes zoster (shingles).

255 ZV) is the causative agent of chickenpox and herpes zoster (shingles).

256 e immunogenicity and safety of an adjuvanted herpes zoster subunit (HZ/su) vaccine when coadministere

257 (HIV)-infected persons have higher rates of herpes zoster than HIV-uninfected individuals.

258 We evaluated pediatric herpes zoster trends using administrative databases.

259 prednisone and two with CsA), and localized herpes zoster (two with IVCY).

260 thod to assess the safety of live attenuated herpes zoster vaccination during 2011-2017 in US adults

261 INTERPRETATION: The herpes zoster vaccination programme in England has had a

262 In 2013, a herpes zoster vaccination programme was introduced in En

263 We identified individual data on herpes zoster vaccinations administered and consultation

264 Live attenuated herpes zoster vaccine (HZV) reduces that risk, although

265 Herpes zoster vaccine (ZV) was administered as a second

266 Eighty-eight percent of providers recommend herpes zoster vaccine and 41% strongly recommend it, com

267 Physicians are making efforts to provide herpes zoster vaccine but are hampered by barriers, part

268 Efforts to facilitate the financing of herpes zoster vaccine could help increase its use.

269 Herpes zoster vaccine for persons aged 50 years does not

270 The licensing of herpes zoster vaccine has demonstrated that therapeutic

271 Of respondents who began administering herpes zoster vaccine in their office, 12% stopped becau

272 The herpes zoster vaccine is effective in preventing herpes

273 Only 45% of respondents knew that herpes zoster vaccine is reimbursed through Medicare Par

274 The herpes zoster vaccine is the most expensive vaccine reco

275 Herpes zoster vaccine is well tolerated in older, immuno

276 Single dose of herpes zoster vaccine or placebo.

277 Herpes zoster vaccine recipients were more likely to be

278 dults aged 60 years or older, receipt of the herpes zoster vaccine was associated with a lower incide

279 o speak English and Spanish who received the herpes zoster vaccine were compared with 66 patients who

280 ugh prelicensure data provided evidence that herpes zoster vaccine works in a select study population

281 wed, in addition to the effectiveness of the herpes zoster vaccine.

282 tinued to increase since introduction of the herpes zoster vaccines.

283 rated and estimated vaccine efficacy against herpes zoster was 16.8% (95% CI -17.8 to 41.3).

284 Overall vaccine efficacy against herpes zoster was 97.2% (95% confidence interval [CI], 9

285 Incidence of recurrent herpes zoster was compared between the vaccinated and th

286 During a mean follow-up of 3.2 years, herpes zoster was confirmed in 6 participants in the vac

287 Incidence of herpes zoster was evaluated in 663 patients with relapse

288 In the main analysis, the rate of herpes zoster was higher among users of statins relative

289 The case of herpes zoster was relatively mild and resolved without c

290 Herpes zoster was reported by one (<1%) patient on conti

291 An unrecognized case of herpes zoster was the likely source.

292 l outcomes of myocardial infarction (MI) and herpes zoster were also studied.

293 e medical conditions, suggesting results for herpes zoster were not due to bias.

294 immunization and development of varicella or herpes zoster were noted.

295 patients with clinical evidence of localized herpes zoster were randomized to receive oral valacyclov

296 Fifty-four patients with herpes zoster were treated with valacyclovir.

297 Serious or complicated cases of herpes zoster were uncommon.

298 Reactivation from latency causes herpes zoster, which may be complicated by postherpetic

299 who had received varicella vaccine developed herpes zoster with meningitis.

300 Information on the risks of herpes zoster (zoster) preceding a cancer diagnosis and